Latest Stock Buy or Sell? Make More Informed Decisions!

Potash and the other fertilizer stocks can do well from late June until the end of the year. However, the real sweet spot is October and into the end of the year. If it is able to go above its current level that would actually be positive.

The long-term uranium story is good. Recently there has been a consolidation in the stock price. Technically the stock is in a channel, and currently we are in the top end of it. Being at the top of the channel doesn’t mean that this is going to go back down to the $15 level. We are getting close to the seasonal standpoint where this stock does do well. It tends to pick up a little bit in November. He is looking for it to move above $20 and move higher.

Seasonally we have finished the period for the utility sector. Good company, but he would be looking to move on as there are other opportunities to provide better growth potential.

Technology tends to do well at this time of the year. There have been some good earnings. Right now there are opportunities for it to continue to do well. In November, on average, it produces a 2.6% rate of return, and has been positive 68% of the time.

Has performed poorly so far. It was badly beaten up because they over promised at the beginning of the year, and didn’t live up to that promise, but are now showing signs of shaping up. They are going to boost their overall buyback to $12 billion in shares. It tends to do well at this time of the year.

Canadian Banks have been badly beaten up because a) everybody expects the house prices to collapse, b) oil prices are going to have an impact at some point and c) US hedge funds are Short Selling banks. Recently there have been some positive performances for the banks. We are now in the seasonal period for banks and they are showing outperformance signs. He is expecting that to continue on.

Markets. In the last 8 weeks, portfolio managers have really had to earn their keep. It has been really confusing, a lot of noise, a lot of leadership changing in the market. It felt like things were going to go the wrong way. The complexity of all these different macro economic factors, things that most investors have to pay attention to that you never did in your life before. Everybody is a Fed expert. The whole community has been egregiously wrong on what is happening with rates. What he has found to work in his approach is to just focus on incredibly good companies.

Trimmed his position by a 3^rd on April 28 and trimmed again on August 25. Finally got stopped out and had no idea it would drop another 55%. (Stops do work.) The 1^st 2 positions were 150% gains and the last position was about 100% gain. There is a very fiery presidential election going on, so there is certain unjust characteristic to the whole Pharma space with pricing, etc. Leveraged growth through acquisition is another issue that is playing. The topic of drug pricing is going to be forefront in conversations for at least a couple of months. This might be dead money for a while.

Not a name he would want to own. They have more price sensitive areas of the market, so they don’t really have the ability to set prices as well as they would like. Also, has a very light R&D budget, which is something you don’t want from a pharma company. Right now they are in a joint venture with Pfizer (PFE-N) on an HIV company, and the earnings and cash flow from that are not expected for another couple of years. You might consider iShares US Healthcare ETF (IYH-N) instead.

Had been a core holding of his for quite some time and an example of where Stops worked quite nicely. It was very encouraging to see a good move on this today. Cyclicals can be a really frustrating round-trip for a lot of people, so he tends to shy away from these.

An excellent company and he is a big believer in their story in the US.

Completely comfortable owning this. Doesn’t see any reason to make a wholehearted switch out of this and into something else. Thinks this is undervalued and that their dividend is going up. Their enterprise has grown at something like 65%. 1.8% dividend yield.

(A Top Pick Dec 16/14. Up 8.12%.) Got a little bit worried about this in September. One of those names that you want to continue to own. Fairly valued at this point, so wait until it gets back down to around $70.

(A Top Pick Dec 16/14. Up 62.06%.) Well-managed. This is something that you want to own.

(A Top Pick Dec 16/14. Up 7.66%.) This is more than a car company. He no longer owns this, but it is something that he would like to have back because it is going to be a really interesting innovative story over time.